

Manuel Comabella

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3532069/manuel-comabella-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

227
papers

11,643
citations

49
h-index

103
g-index

248
ext. papers

14,165
ext. citations

6.8
avg, IF

5.73
L-index

#	Paper	IF	Citations
227	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. <i>Nature</i> , 2011 , 476, 214-9	50.4	1948
226	Neurofilaments as biomarkers in neurological disorders. <i>Nature Reviews Neurology</i> , 2018 , 14, 577-589	15	627
225	A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. <i>Neurology</i> , 2009 , 73, 1914-22	6.5	470
224	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. <i>Science</i> , 2019 , 365,	33.3	309
223	Defining high, medium and low impact prognostic factors for developing multiple sclerosis. <i>Brain</i> , 2015 , 138, 1863-74	11.2	302
222	Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?. <i>Neurology</i> , 2008 , 70, 1079-83	6.5	265
221	Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. <i>Annals of Neurology</i> , 2006 , 59, 344-52	9.4	260
220	Baseline MRI predicts future attacks and disability in clinically isolated syndromes. <i>Neurology</i> , 2006 , 67, 968-72	6.5	209
219	Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. <i>Brain</i> , 2010 , 133, 1082-93	11.2	197
218	Measures in the first year of therapy predict the response to interferon beta in MS. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 848-53	5	182
217	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1013-24	5	181
216	Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. <i>Journal of Clinical Investigation</i> , 1998 , 102, 671-8	15.9	169
215	A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. <i>Brain</i> , 2009 , 132, 3353-65	11.2	168
214	Body fluid biomarkers in multiple sclerosis. <i>Lancet Neurology, The</i> , 2014 , 13, 113-26	24.1	157
213	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1005-15	5.5	157
212	Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. <i>Annals of Neurology</i> , 2010 , 67, 159-69	9.4	145
211	Plasma osteopontin levels in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2005 , 158, 231-9	3.5	143

210	Brainstem lesions in clinically isolated syndromes. <i>Neurology</i> , 2010 , 75, 1933-8	6.5	136
209	Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. <i>Archives of Neurology</i> , 2008 , 65, 337-44		135
208	Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. <i>American Journal of Human Genetics</i> , 2013 , 92, 854-65	11	132
207	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 8, 111-126	5.2	128
206	Transcription-based prediction of response to IFNbeta using supervised computational methods. <i>PLoS Biology</i> , 2005 , 3, e2	9.7	122
205	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. <i>Brain</i> , 2015 , 138, 918-31	11.2	103
204	FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. <i>Nature Medicine</i> , 2014 , 20, 272-82	50.5	103
203	Predicting responders to therapies for multiple sclerosis. <i>Nature Reviews Neurology</i> , 2009 , 5, 553-60	15	101
202	Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1802-9	5	99
201	Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 479-84	5	97
200	Tumor necrosis factor alpha (TNF- α) anti-TNF- α and demyelination revisited: an ongoing story. <i>Journal of Neuroimmunology</i> , 2011 , 234, 1-6	3.5	94
199	Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. <i>Archives of Neurology</i> , 2009 , 66, 972-8		94
198	Immunopathogenesis of multiple sclerosis. <i>Clinical Immunology</i> , 2012 , 142, 2-8	9	93
197	Is optic neuritis more benign than other first attacks in multiple sclerosis?. <i>Annals of Neurology</i> , 2005 , 57, 210-5	9.4	93
196	Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. <i>Annals of Neurology</i> , 2002 , 52, 400-6	9.4	89
195	Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. <i>PLoS ONE</i> , 2008 , 3, e3490	3.7	83
194	Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. <i>Brain</i> , 2011 , 134, 693-703	11.2	76
193	NLRP3 inflammasome is associated with the response to IFN- β in patients with multiple sclerosis. <i>Brain</i> , 2015 , 138, 644-52	11.2	75

192	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. <i>Brain</i> , 2018 , 141, 1085-1093	11.2	72
191	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. <i>Cell</i> , 2018 , 175, 1679-1687.e772	11.2	72
190	The autoimmune disease-associated KIF5A, CD226 and SH2B3 gene variants confer susceptibility for multiple sclerosis. <i>Genes and Immunity</i> , 2010 , 11, 439-45	4.4	71
189	Neurofilament ELISA validation. <i>Journal of Immunological Methods</i> , 2010 , 352, 23-31	2.5	69
188	The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. <i>Brain</i> , 2018 , 141, 1075-1084	11.2	64
187	Neurofilament light chain level is a weak risk factor for the development of MS. <i>Neurology</i> , 2016 , 87, 1076-84	6.5	61
186	COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. <i>European Journal of Neurology</i> , 2021 , 28, 3384-3395	6	60
185	Circulating microparticles reflect treatment effects and clinical status in multiple sclerosis. <i>Biomarkers in Medicine</i> , 2014 , 8, 653-61	2.3	59
184	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016ECTRIMS focused workshop. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 590-603	5	58
183	Genomics in multiple sclerosis--current state and future directions. <i>Journal of Neuroimmunology</i> , 2007 , 187, 1-8	3.5	58
182	Metabolomic signatures associated with disease severity in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e321	9.1	57
181	PML risk stratification using anti-JCV antibody index and L-selectin. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1048-60	5	57
180	Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 301-312	5	55
179	A cytokine gene screen uncovers SOCS1 as genetic risk factor for multiple sclerosis. <i>Genes and Immunity</i> , 2012 , 13, 21-8	4.4	49
178	Targeting dendritic cells to treat multiple sclerosis. <i>Nature Reviews Neurology</i> , 2010 , 6, 499-507	15	48
177	MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. <i>Brain</i> , 2013 , 136, 1778-82	11.2	47
176	Multiple sclerosis: current treatment algorithms. <i>Current Opinion in Neurology</i> , 2011 , 24, 230-7	7.1	47
175	Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 322-330	5	45

174	Transcriptomics: mRNA and alternative splicing. <i>Journal of Neuroimmunology</i> , 2012 , 248, 23-31	3.5	45
173	Identification of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus associated with multiple sclerosis. <i>Journal of Medical Genetics</i> , 2013 , 50, 25-33	5.8	45
172	Do multimodal evoked potentials add information to MRI in clinically isolated syndromes?. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 55-61	5	45
171	Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. <i>Journal of Neurology</i> , 2007 , 254, 827-37	5.5	45
170	Serum neurofilament light as a biomarker in progressive multiple sclerosis. <i>Neurology</i> , 2020 , 95, 436-444	6.5	44
169	Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. <i>Annals of Neurology</i> , 2015 , 77, 447-57	9.4	43
168	Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. <i>Clinical Immunology</i> , 2011 , 141, 348-56	9	43
167	Interferon-beta treatment alters peripheral blood monocytes chemokine production in MS patients. <i>Journal of Neuroimmunology</i> , 2002 , 126, 205-12	3.5	43
166	Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis. <i>Annals of Neurology</i> , 2014 , 76, 231-40	9.4	42
165	Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. <i>European Journal of Neurology</i> , 2012 , 19, 899-904	6	42
164	Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. <i>Brain</i> , 2015 , 138, 632-43	11.2	42
163	N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. <i>Journal of Neurology</i> , 2014 , 261, 2338-43	5.5	42
162	Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 39-43	5	42
161	Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 983-90	5	41
160	NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients. <i>Brain</i> , 2020 , 143, 1414-1430	11.2	41
159	Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. <i>Multiple Sclerosis International</i> , 2011 , 2011, 246412	1.1	40
158	Search for specific biomarkers of IFN β bioactivity in patients with multiple sclerosis. <i>PLoS ONE</i> , 2011 , 6, e23634	3.7	40
157	Significant clinical worsening after natalizumab withdrawal: Predictive factors. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 780-5	5	37

156	Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. <i>Neurology</i> , 2016 , 87, 1368-74	6.5	37
155	Precision medicine in multiple sclerosis: biomarkers for diagnosis, prognosis, and treatment response. <i>Current Opinion in Neurology</i> , 2016 , 29, 254-62	7.1	37
154	ANKRD55 and DHCR7 are novel multiple sclerosis risk loci. <i>Genes and Immunity</i> , 2012 , 13, 253-7	4.4	37
153	Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. <i>Clinical Immunology</i> , 2009 , 130, 145-50	9	36
152	Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 577-87	5	35
151	Pharmacogenomics and multiple sclerosis: moving toward individualized medicine. <i>Current Neurology and Neuroscience Reports</i> , 2011 , 11, 484-91	6.6	35
150	Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain. <i>European Journal of Neurology</i> , 2018 , 25, 1189-1191	6	35
149	Interferon β 1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up. <i>Archives of Neurology</i> , 2011 , 68, 1421-7		34
148	Biomarkers in Multiple Sclerosis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019 , 9,	5.4	34
147	Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1602-8	5	33
146	Implication of the Toll-like receptor 4 pathway in the response to interferon- β in multiple sclerosis. <i>Annals of Neurology</i> , 2011 , 70, 634-45	9.4	33
145	A genomic screen of Spanish multiple sclerosis patients reveals multiple loci associated with the disease. <i>Journal of Neuroimmunology</i> , 2003 , 143, 124-8	3.5	33
144	Altered maturation of circulating dendritic cells in primary progressive MS patients. <i>Journal of Neuroimmunology</i> , 2006 , 175, 183-91	3.5	32
143	Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. <i>Neurology</i> , 2019 , 92, e1507-e1516	6.5	31
142	Treatment with MOG-DNA vaccines induces CD4+CD25+FoxP3+ regulatory T cells and up-regulates genes with neuroprotective functions in experimental autoimmune encephalomyelitis. <i>Journal of Neuroinflammation</i> , 2012 , 9, 139	10.1	31
141	Replication of top markers of a genome-wide association study in multiple sclerosis in Spain. <i>Genes and Immunity</i> , 2011 , 12, 110-5	4.4	31
140	The Multiple Sclerosis Genomic Map: Role of peripheral immune cells and resident microglia in susceptibility		31
139	Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferon β therapy in multiple sclerosis. <i>Genes and Immunity</i> , 2011 , 12, 466-72	4.4	30

138	DNA-based vaccines for multiple sclerosis: current status and future directions. <i>Clinical Immunology</i> , 2012 , 142, 76-83	9	29
137	Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk. <i>Journal of Medical Genetics</i> , 2013 , 50, 140-3	5.8	29
136	A functional variant that affects exon-skipping and protein expression of SP140 as genetic mechanism predisposing to multiple sclerosis. <i>Human Molecular Genetics</i> , 2015 , 24, 5619-27	5.6	28
135	Power estimation for non-standardized multisite studies. <i>NeuroImage</i> , 2016 , 134, 281-294	7.9	28
134	HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2009 , 210, 116-9	3.5	28
133	Genome-wide significant association with seven novel multiple sclerosis risk loci. <i>Journal of Medical Genetics</i> , 2015 , 52, 848-55	5.8	27
132	Plasma chitotriosidase activity in multiple sclerosis. <i>Clinical Immunology</i> , 2009 , 131, 216-22	9	27
131	Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. <i>PLoS ONE</i> , 2017 , 12, e0170395	3.7	27
130	Cytokine profiles show heterogeneity of interferon- γ response in multiple sclerosis patients. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016 , 3, e202	9.1	26
129	Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. <i>Neurology</i> , 2014 , 83, 1210-6	6.5	26
128	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 912-923	5	26
127	Roles of the ubiquitin peptidase USP18 in multiple sclerosis and the response to interferon- γ treatment. <i>European Journal of Neurology</i> , 2013 , 20, 1390-7	6	24
126	Replication study of 10 genes showing evidence for association with multiple sclerosis: validation of TMEM39A, IL12B and CBLB [correction of CLBL] genes. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 959-65	5	24
125	MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes. <i>Human Molecular Genetics</i> , 2016 , 25, 308-16	5.6	23
124	Baseline gene expression signatures in monocytes from multiple sclerosis patients treated with interferon-beta. <i>PLoS ONE</i> , 2013 , 8, e60994	3.7	23
123	Role of tumour necrosis factor (TNF)- β and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis. <i>Clinical and Experimental Immunology</i> , 2011 , 166, 338-45	6.2	23
122	Pharmacogenomics in neurology: current state and future steps. <i>Annals of Neurology</i> , 2011 , 70, 684-97	9.4	23
121	Gender-associated differences of perforin polymorphisms in the susceptibility to multiple sclerosis. <i>Journal of Immunology</i> , 2010 , 185, 5392-404	5.3	23

120	Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2015 , 12, 48	10.1	22
119	Ancient and recent selective pressures shaped genetic diversity at AIM2-like nucleic acid sensors. <i>Genome Biology and Evolution</i> , 2014 , 6, 830-45	3.9	22
118	Validation of semaphorin 7A and ala-His-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2014 , 11, 181	10.1	22
117	Protein-Based Classifier to Predict Conversion from Clinically Isolated Syndrome to Multiple Sclerosis. <i>Molecular and Cellular Proteomics</i> , 2016 , 15, 318-28	7.6	21
116	Risk acceptance in multiple sclerosis patients on natalizumab treatment. <i>PLoS ONE</i> , 2013 , 8, e82796	3.7	21
115	Genetic association between polymorphisms in the ADAMTS14 gene and multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2005 , 164, 140-7	3.5	21
114	Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis. <i>Journal of Neurology</i> , 2008 , 255, 1136-41	5.5	20
113	Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. <i>Pharmacogenomics Journal</i> , 2017 , 17, 312-318	3.5	19
112	NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk. <i>Neuron</i> , 2016 , 92, 333-335	13.9	19
111	Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis. <i>CNS Drugs</i> , 2016 , 30, 41-51	6.7	19
110	TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis. <i>Neurology</i> , 2013 , 80, 2010-6	6.5	19
109	Lesion topographies in multiple sclerosis diagnosis: A reappraisal. <i>Neurology</i> , 2017 , 89, 2351-2356	6.5	19
108	Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1193-6	5	19
107	Orchestrating innate immune responses in multiple sclerosis: molecular players. <i>Journal of Neuroimmunology</i> , 2010 , 225, 5-12	3.5	19
106	Decreased MMP-9 production in primary progressive multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 376-80	5	19
105	Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS. <i>Journal of Neurology</i> , 2010 , 257, 742-6	5.5	18
104	The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1658-1669	5	18
103	Multiple sclerosis, and other demyelinating and autoimmune inflammatory diseases of the central nervous system. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2017 , 146, 67-84	3	18

102	Concise review: modeling multiple sclerosis with stem cell biological platforms: toward functional validation of cellular and molecular phenotypes in inflammation-induced neurodegeneration. <i>Stem Cells Translational Medicine</i> , 2015 , 4, 252-60	6.9	17
101	CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. <i>Neurology</i> , 2016 , 87, 2491-2494	6.5	17
100	HLA alleles as biomarkers of high-titre neutralising antibodies to interferon- β therapy in multiple sclerosis. <i>Journal of Medical Genetics</i> , 2014 , 51, 395-400	5.8	17
99	IL28B polymorphisms are not associated with the response to interferon- β in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2011 , 239, 101-4	3.5	16
98	IFN-beta pharmacogenomics in multiple sclerosis. <i>Pharmacogenomics</i> , 2010 , 11, 1137-48	2.6	16
97	The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 18-33	5	16
96	Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN- β . <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015 , 2, e154	9.1	15
95	Antiviral immune response in patients with multiple sclerosis and healthy siblings. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 355-8	5	15
94	Value of NMO-IgG determination at the time of presentation as CIS. <i>Neurology</i> , 2012 , 78, 1608-11	6.5	15
93	EBV-specific immune responses in patients with multiple sclerosis responding to IFN- β therapy. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 605-9	5	15
92	Up-regulation of inducible heat shock protein-70 expression in multiple sclerosis patients. <i>Autoimmunity</i> , 2014 , 47, 127-33	3	14
91	SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 524-31	5	14
90	Differential susceptibility to apoptosis of CD4+T cells expressing CCR5 and CXCR3 in patients with MS. <i>Clinical Immunology</i> , 2009 , 133, 364-74	9	14
89	Deficient Fas expression by CD4+ CCR5+ T cells in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2006 , 180, 147-58	3.5	14
88	TNF-alpha converting enzyme (TACE) protein expression in different clinical subtypes of multiple sclerosis. <i>Journal of Neurology</i> , 2006 , 253, 701-6	5.5	14
87	Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course. <i>Journal of Neuroinflammation</i> , 2018 , 15, 265	10.1	14
86	Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysis. <i>Journal of Neuroimmunology</i> , 2015 , 278, 277-9	3.5	13
85	Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , 2017 , 82, 186-195	9.4	13

84	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , 2020 , 17, e1003348	11.6	13
83	Simultaneous CMV and infection following alemtuzumab treatment for multiple sclerosis. <i>Neurology</i> , 2019 , 92, 296-298	6.5	13
82	Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis. <i>Journal of Interferon and Cytokine Research</i> , 2010 , 30, 727-32	3.5	12
81	Novel Insights into the Multiple Sclerosis Risk Gene ANKRD55. <i>Journal of Immunology</i> , 2016 , 196, 4553-65	3.3	12
80	Circulating levels of soluble apoptosis-related molecules in patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2013 , 263, 152-4	3.5	11
79	Genetic association of CASP8 polymorphisms with primary progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2010 , 222, 70-5	3.5	10
78	Effect of Specific Mutations in Cd300 Complexes Formation; Potential Implication of Cd300f in Multiple Sclerosis. <i>Scientific Reports</i> , 2017 , 7, 13544	4.9	9
77	Analysis of the IL28RA locus as genetic risk factor for multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2012 , 245, 98-101	3.5	9
76	United Europeans for development of pharmacogenomics in multiple sclerosis network. <i>Pharmacogenomics</i> , 2009 , 10, 885-94	2.6	9
75	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. <i>Journal of Neuroimmunology</i> , 2019 , 326, 19-27	3.5	9
74	Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2017 , 303, 62-65	3.5	8
73	Activation-induced cell death in T lymphocytes from multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2014 , 272, 51-5	3.5	8
72	Cell-specific effects in different immune subsets associated with SOCS1 genotypes in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1498-512	5	8
71	Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2014 , 1, e47	9.1	8
70	Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients. <i>G3: Genes, Genomes, Genetics</i> , 2016 , 6, 2073-9	3.2	8
69	Native ancestry is associated with optic neuritis and age of onset in hispanics with multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1362-1371	5.3	8
68	Molecular dynamics and intracellular signaling of the TNF-R1 with the R92Q mutation. <i>Journal of Neuroimmunology</i> , 2015 , 289, 12-20	3.5	7
67	Interferon-beta affects mitochondrial activity in CD4+ lymphocytes: Implications for mechanism of action in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1262-70	5	7

66	Chitinase 3-like 1 is neurotoxic in primary cultured neurons. <i>Scientific Reports</i> , 2020 , 10, 7118	4.9	7
65	Generation of six multiple sclerosis patient-derived induced pluripotent stem cell lines. <i>Stem Cell Research</i> , 2017 , 24, 155-159	1.6	7
64	Decreased soluble IFN- γ receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 937-945	5	7
63	Genetic analysis of SLC11A1 polymorphisms in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 618-20	5	7
62	Targeting Inflammasomes to Treat Neurological Diseases. <i>Annals of Neurology</i> , 2021 , 90, 177-188	9.4	7
61	The genetic diversity of multiple sclerosis risk among Hispanic and African American populations living in the United States. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1329-1339	5	7
60	The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 913-921	5	7
59	Levels of soluble TNF-RII are increased in serum of patients with primary progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014 , 271, 56-9	3.5	6
58	Genetic association between polymorphisms in the BTG1 gene and multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2009 , 213, 142-7	3.5	6
57	Optic Nerve Topography in Multiple Sclerosis Diagnosis: The Utility of Visual Evoked Potentials. <i>Neurology</i> , 2021 , 96, e482-e490	6.5	6
56	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. <i>Neurology</i> , 2021 , 97, e1641-e1652	6.5	6
55	An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis. <i>Revista De Neurologia</i> , 2011 , 52, 321-30	24	6
54	Are Leber's mitochondrial DNA mutations associated with aquaporin-4 autoimmunity?. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 393-4	5	5
53	Peripheral blood non-MAIT CD8+CD161hi cells are decreased in relapsing-remitting multiple sclerosis patients treated with interferon beta. <i>Journal of Neuroimmunology</i> , 2015 , 288, 98-101	3.5	5
52	Nerve conduction velocity is regulated by the inositol polyphosphate-4-phosphatase II gene. <i>American Journal of Pathology</i> , 2014 , 184, 2420-9	5.8	5
51	TRPM4 mRNA expression levels in peripheral blood mononuclear cells from multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2013 , 261, 146-8	3.5	5
50	Short commentary on the consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 129-32	5	5
49	Plasma levels of 15d-PGJ are not altered in multiple sclerosis. <i>European Journal of Neurology</i> , 2009 , 16, 1197-201	6	5

48	B cell expression of the inhibitory Fc gamma receptor is unchanged in early MS. <i>Journal of Neuroimmunology</i> , 2010 , 223, 135-7	3.5	5
47	Evidence for association of chromosome 10 open reading frame (C10orf27) gene polymorphisms and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 412-4	5	5
46	New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab. <i>Frontiers in Neurology</i> , 2020 , 11, 579438	4.1	5
45	Chitinases and chitinase-like proteins as biomarkers in neurologic disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	5
44	CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	5
43	NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1507-1510	5	5
42	Circulating EZH2-positive T cells are decreased in multiple sclerosis patients. <i>Journal of Neuroinflammation</i> , 2018 , 15, 296	10.1	5
41	Late-onset metachromatic leukodystrophy clinically presenting as isolated peripheral neuropathy: compound heterozygosity for the IVS2+1G-->A mutation and a newly identified missense mutation (Thr408Ile) in a Spanish family. <i>Annals of Neurology</i> , 2001 , 50, 108-12	9.4	5
40	Radiologically isolated syndrome: targeting miRNAs as prognostic biomarkers. <i>Epigenomics</i> , 2020 , 12, 2065-2076	4.4	4
39	Tocilizumab and multiple sclerosis: a causal relationship? Clinical Commentary on the case report entitled--MS arising during Tocilizumab therapy for rheumatoid arthritis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 257-8	5	4
38	Influence of the LILRA3 Deletion on Multiple Sclerosis Risk: Original Data and Meta-Analysis. <i>PLoS ONE</i> , 2015 , 10, e0134414	3.7	4
37	Cellular immune responses in multiple sclerosis patients treated with interferon-beta. <i>Clinical and Experimental Immunology</i> , 2013 , 171, 243-6	6.2	4
36	Polyregional and hemispheric syndromes: a study of these uncommon first attacks in a CIS cohort. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 731-6	5	4
35	Breast regression protein-39 is not required for experimental autoimmune encephalomyelitis induction. <i>Clinical Immunology</i> , 2015 , 160, 133-41	9	3
34	Increased expression of dedicator-cytokinesis-10, caspase-2 and Synaptotagmin-like 2 is associated with clinical disease activity in multiple sclerosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2016 , 1,	0	3
33	Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1535-1538	5	3
32	Decision tree based fuzzy classifier of magnetic resonance spectra from cerebrospinal fluid samples. <i>Fuzzy Sets and Systems</i> , 2011 , 170, 43-63	3.7	3
31	Association Cluster Detector: a tool for heuristic detection of significance clusters in whole-genome scans. <i>Bioinformatics</i> , 2005 , 21 Suppl 2, ii180-1	7.2	3

30	Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022 , 9,	9.1	3
29	Modelling multiple sclerosis using induced pluripotent stem cells. <i>Journal of Neuroimmunology</i> , 2020 , 349, 577425	3.5	3
28	Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2021 , 12, 685139	8.4	3
27	Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients. <i>Journal of Neurology</i> , 2021 , 1	5.5	3
26	A Polymorphism Within the Gene Is Associated With a Higher Relapse Number in Male Patients of Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2020 , 11, 771	8.4	2
25	Should we systematically test patients with clinically isolated syndrome for auto-antibodies?. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1802-10	5	2
24	A case of neuromyelitis optica harboring both anti-aquaporin-4 antibodies and a pathogenic mitochondrial DNA mutation for Leber's hereditary optic neuropathy: clinical commentary. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 261	5	2
23	Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	2
22	CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211010082	5	2
21	Angiogenin in the Neurogenic Subventricular Zone After Stroke. <i>Frontiers in Neurology</i> , 2021 , 12, 662235	4.1	2
20	CSF Chitinase 3-Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	2
19	No association of IFI16 (interferon-inducible protein 16) variants with susceptibility to multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014 , 271, 49-52	3.5	1
18	Treatment with interferon- β does not induce anti-nuclear and anti-neuronal serum autoantibodies in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2013 , 255, 102-4	3.5	1
17	DNA Vaccination Techniques. <i>Methods in Molecular Biology</i> , 2016 , 1304, 39-50	1.4	1
16	Pharmacogenomics in multiple sclerosis: getting the right medicine to the right patient. <i>Therapy: Open Access in Clinical Medicine</i> , 2008 , 5, 623-629		1
15	A pharmacogenetic study implicates in the response to Interferon- β in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1074-1082	5	1
14	Immunomodulatory Effects Associated with Cladribine Treatment.. <i>Cells</i> , 2021 , 10,	7.9	1
13	Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221089540	5	1

12	Targeted resequencing reveals rare variants enrichment in multiple sclerosis susceptibility genes. <i>Human Mutation</i> , 2020 , 41, 1308-1320	4.7	○
11	Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.. <i>Journal of Neurology</i> , 2022 , 269, 1764	5.5	○
10	Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the - Gene Region in Immature Dendritic Cells.. <i>Frontiers in Immunology</i> , 2021 , 12, 816930	8.4	○
9	Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211053001	5	○
8	Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab. <i>Frontiers in Immunology</i> , 2021 , 12, 760546	8.4	○
7	Chitinase 3-like 1 is not a target antigen in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1455-1457	5	○
6	Inflammation in multiple sclerosis induces a specific reactive astrocyte state driving non-cell-autonomous neuronal damage.. <i>Clinical and Translational Medicine</i> , 2022 , 12, e837	5.7	○
5	Reply. <i>Annals of Neurology</i> , 2017 , 82, 647-648	9.4	
4	Risk of multiple sclerosis in children with acute demyelination. <i>Lancet Neurology</i> , 2011 , 10, 399-400	24.1	
3	Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis1 / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking. <i>Laboratoriums Medizin</i> , 2010 , 34, 1-12		
2	Reply: Plasma chitotriosidase activity in multiple sclerosis. <i>Clinical Immunology</i> , 2009 , 133, 284	9	
1	Biomarkers26-55		